PET Imaging in Alzheimer’s Disease
Article Sidebar
Published:
Feb 20, 2013
Keywords:
PET, FDG, amyloid, brain, dementia,Alzheimer’s disease
Main Article Content
Abstract
Dementia is a common disease in the elderly with a rising incidence with increasing age. Diagnosis is crucial for determining patient care and directing the lines of treatment to decrease the rate of dementia progression.
Article Details
How to Cite
1.
Tepmongkol S. PET Imaging in Alzheimer’s Disease. BKK Med J [Internet]. 2013 Feb. 20 [cited 2024 Nov. 22];5:76. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/218096
Issue
Section
Reviews Article
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Carpenter BD, Xiong C, Porensky EK, et al. Reaction to a dementia diagnosis in individuals with Alzheimer’s disease and mild Cognitive Impairment. J Am Geriatr Soc 2008;56:405-12.
2. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-48.
3. Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011;8:82-92.
4. Cummings JL. Alzheimer’s disease.N Engl J Med 2004;351:56-67.
5. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44.
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
7. Scheltens P. Imaging in Alzheimer’s disease. Dialogues Clin Neurosci 2009;11:191-9.
8. Gelosa G, Brooks DJ. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging 2012;39:1207-19.
9. Mori T, Maeda J, Shimada H, et al. Molecular imaging of dementia. Psychogeriatrics 2012;12:106-14.
10. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-65.
11. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46:1625-32.
12. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.Arch Gen Psychiatry 2009;66:81-7.
13. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 2011; 26:627-45.
14. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-8.
15. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement 2012;8:389-98.
16. Silverman DH, Small GW, Phelps ME. Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer’s Disease. Clin Positron Imaging 1999;2:119-30.
17. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008;7:161-72.
18. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-92.
19. Nestor PJ, Caine D, Fryer TD, et al. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET. J Neurol Neurosurg Psychiatry 2003;74:1521-9.
20. Shimada A, Hashimoto H, Kawabe J, et al. Evaluation of therapeutic response to donepezil by positron emission tomography. Osaka City Med J 2011;57:11-9.
21. Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012;9:8.
22. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer’s disease. J Alzheimers Dis 2011;26:337-48.
2. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-48.
3. Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011;8:82-92.
4. Cummings JL. Alzheimer’s disease.N Engl J Med 2004;351:56-67.
5. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939-44.
6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
7. Scheltens P. Imaging in Alzheimer’s disease. Dialogues Clin Neurosci 2009;11:191-9.
8. Gelosa G, Brooks DJ. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging 2012;39:1207-19.
9. Mori T, Maeda J, Shimada H, et al. Molecular imaging of dementia. Psychogeriatrics 2012;12:106-14.
10. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-65.
11. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005;46:1625-32.
12. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.Arch Gen Psychiatry 2009;66:81-7.
13. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 2011; 26:627-45.
14. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-8.
15. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement 2012;8:389-98.
16. Silverman DH, Small GW, Phelps ME. Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer’s Disease. Clin Positron Imaging 1999;2:119-30.
17. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008;7:161-72.
18. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-92.
19. Nestor PJ, Caine D, Fryer TD, et al. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET. J Neurol Neurosurg Psychiatry 2003;74:1521-9.
20. Shimada A, Hashimoto H, Kawabe J, et al. Evaluation of therapeutic response to donepezil by positron emission tomography. Osaka City Med J 2011;57:11-9.
21. Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012;9:8.
22. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer’s disease. J Alzheimers Dis 2011;26:337-48.